"Wegovy's Heart-Protective Effects Boost Novo Nordisk Shares"

Novo Nordisk's shares surged after late-stage trial data revealed that its obesity drug, Wegovy, reduced the risk of major cardiovascular events by 20% compared to a placebo. The results of the SELECT trial exceeded expectations and could help reshape Wegovy's perception as a "vanity drug." The trial involved over 17,600 adults with cardiovascular disease who were overweight or obese but had no history of diabetes. Novo Nordisk plans to seek regulatory approvals for an expanded label indication for Wegovy in the US and European Union this year. The detailed results of the trial will be presented at a later scientific conference.